Dalrymple-Alford J C, Jamieson C F, Donaldson I M
Department of Psychology, University of Canterbury, Christchurch, New Zealand.
Clin Neuropharmacol. 1995 Aug;18(4):348-59. doi: 10.1097/00002826-199508000-00007.
The influence of selegiline (5 mg b.i.d.) on cognition of 20 levodopanaive patients with early Parkinson's disease (PD) was examined in an 8-week, randomized, placebo-controlled, double-blind trial. Clinical evaluations and cognitive tests were administered at baseline and at 8 weeks; patients with PD who received placebo were also examined 8 weeks after subsequent selegiline treatment. By comparison with non-PD controls, patients with PD were impaired on the Wisconsin card sorting task and on the advanced progressive matrices test, but not in terms of their performance on the Rivermead behavioral memory test or on the rod (spatial) orientation test. Selegiline improved scores on the mentation/mood part and the activities of daily living part of the Unified Parkinson's Disease Rating Scale, but it did not improve motor scores on this test, nor did it have clear effects on the specific neuropsychological measures that were examined.
在一项为期8周的随机、安慰剂对照、双盲试验中，研究了司来吉兰（5毫克，每日两次）对20例早期帕金森病（PD）初治患者认知功能的影响。在基线和8周时进行临床评估和认知测试；接受安慰剂的PD患者在后续司来吉兰治疗8周后也进行检查。与非PD对照组相比，PD患者在威斯康星卡片分类任务和高级渐进矩阵测试中表现受损，但在Rivermead行为记忆测试或棒（空间）定向测试中的表现未受损。司来吉兰提高了统一帕金森病评定量表中精神状态/情绪部分和日常生活活动部分的评分，但未改善该测试中的运动评分，对所检查的特定神经心理学指标也无明显影响。
